GSK2330672

Phase 2Small molecule

GSK

GSK2330672 is one of 87 small molecule programs targeting Primary Biliary Cirrhosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Biliary CirrhosisActive, not recruiting

Type 2 DiabetesActive, not recruiting

Primary Biliary CholangitisActive, not recruiting

Primary Biliary CirrhosisPhase 2

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

Primary Biliary CholangitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

55 2

GSK2330672

GSK

Phase 2

2 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Glargine

Eli Lilly

Preclinical

8 5

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 8

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 9

Forxiga

AstraZeneca

Preclinical

3 10

Lovaza

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

Completed· GSK logo

GSK·Phase 2·NCT02202161·70 enrolled

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

Completed· GSK logo

GSK·Phase 2·NCT01929863·16 enrolled

Primary Biliary Cirrhosis1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus

Completed· GSK logo

GSK·Phase 2·NCT01899703·22 enrolled

Interaction1 trial

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT04053023·19 enrolled

Primary Biliary Cholangitis1 trial

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

Completed· GSK logo

GSK·Phase 2·NCT02966834·147 enrolled

Unspecified2 trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.

Completed· GSK logo

GSK·Phase 1·NCT01607385·56 enrolled

First Time in Human Study Using GSK2330672

Completed· GSK logo

GSK·Phase 1·NCT01416324·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for GSK2330672. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK2330672 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK2330672. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

GSK2330672

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes2 trials

Primary Biliary Cirrhosis1 trial

Interaction1 trial

Primary Biliary Cholangitis1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News